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Abstract: S100P protein is a potent inducer of metastasis in a model system, and its presence in 
cancer cells of patients is strongly associated with their reduced survival times. A well-established 
Furth Wistar rat metastasis model system, methods for measuring cell migration, and specific in-
hibitors were used to study pathways of motility-driven metastasis. Cells expressing C-terminal 
mutant S100P proteins display markedly-reduced S100P-driven metastasis in vivo and cell migra-
tion in vitro. These cells fail to display the low focal adhesion numbers observed in cells expressing 
wild-type S100P, and the mutant S100P proteins exhibit reduced biochemical interaction with non-
muscle myosin heavy chain isoform IIA in vitro. Extracellular inhibitors of the S100P-dependent 
plasminogen activation pathway reduce, but only in part, wild-type S100P-dependent cell migra-
tion; they are without effect on S100P-negative cells or cells expressing C-terminal mutant S100P 
proteins and have no effect on the numbers of focal adhesions. Recombinant wild-type S100P pro-
tein, added extracellularly to S100P-negative cells, stimulates cell migration, which is abolished by 
these inhibitors. The results identify at least two S100P-dependent pathways of migration, one cell 
surface and the other intracellularly-linked, and identify its C-terminal lysine as a target for inhib-
iting multiple migration-promoting activities of S100P protein and S100P-driven metastasis.  
Keywords: S100P; membrane; metastasis; cell migration; myosin llA 
 
1. Introduction 
Elevated levels of some EF-hand-containing, calcium-binding members of the S100 
family of proteins are associated with the development of many human cancers [1,2]. In-
creased immunohistochemical levels of S100P are associated with markedly reduced sur-
vival times of patients with breast [3,4], hepatocellular [5], early stage non-small cell lung 
[6], colon [7,8], and ovarian [9,10] cancers. The associations of S100P with reduced patient 
survival times are likely to arise from the ability of S100P to induce a metastatic phenotype 
[3]. However, the molecular pathways by which S100P exerts its metastasis-inducing po-
tential are not yet fully understood [2]. 
The crystal structure of calcium-bound S100P protein shows that it is a homodimer 
with each 95-amino-acid monomer displaying the four α-helical structures common to 
most other S100 proteins [11]. Helix 4 of each monomer ends at amino acid 92, leaving a 
short, three-amino acid, presumably unstructured sequence, GLK, at the C-terminus [11]. 
In the apo-form, the presumably unstructured C-terminal region was found to be six 
amino acid residues longer, KYFEKAGLK, using Nuclear Magnetic Resonance techniques 
[12]. C-terminal regions of other S100 proteins, for example, S100A4 [13], have been re-
ported to be unstructured and dynamic. 
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S100 proteins act by interacting with extracellular and intracellular protein targets 
[14]. Thus, extracellular S100P can interact with the cell-membrane-located RAGE recep-
tor, thereby activating intracellular signalling pathways [15] and with the extracellular 
plasminogen activator, tPA, to enhance plasmin-dependent cell invasion [16], but its rela-
tionship to metastasis is unknown. Intracellular S100P can also interact with cytoskeletal 
proteins, ezrin [17], IQGAP1 [18], and non-muscle myosin II isoforms A (NMMIIA) and 
C (NMMIIC) [19], all with high nM range affinities [17–19], often causing increased cell 
migration [19,20]. In the case of NMMIIA, it has been shown using Fluorescence Lifetime 
Imaging that S100P can interact with NMMIIA in living cells [19]. In cells in which 
NMMIIA had been knocked down using siRNA, S100P induction lost its effect on cell 
migration [19]. Furthermore, in an inducible system, expression of S100P led directly to 
redistribution of NMMIIA filaments and their dissociation. In a cell-free system, S100P 
can partially dissociate myosin IIA filaments [19]. These observations taken together show 
that S100P can interact with myosin IIA in vivo and, through dissociation of the NMMIIA 
filaments, can affect cell migration. It has been shown previously that deletion of the C-
terminal lysines of the related metastasis-inducing protein, S100A4, abrogates its metas-
tasis-inducing potential [21,22] in a well-characterised rat model system of human breast 
cancer metastasis [3,23–25]. We now use this well-characterised rat model system of me-
tastasis to show that deletion of the C-terminal lysine of S100P, or its replacement with 
alanine, reduces the ability of S100P to induce a metastatic phenotype. This approach has 
identified two separate, coexisting S100P-dependent pathways leading to cell migration, 
one linked to the cell surface and one intracellular in the same cell system. 
2. Materials and Methods 
2.1. Site-Directed Mutagenesis and Recombinant Proteins  
 A cDNA encoding the wild-type S100P protein in pET15b vector was subjected to 
site-directed mutagenesis using a Quikchange™ site-directed mutagenesis kit (Strata-
gene, La Jolla, CA) with pairs of complementary oligonucleotide primers to generate 
pET15b vector expressing the two mutant S100Ps, K95A with the C-terminal lysine re-
placed by alanine and ΔK95 S100P with the C-terminal lysine deleted. The identity of these 
proteins was confirmed by mass spectrometry. Details of the site directed mutagenesis, 
production of recombinant protein, and the mass spectrometry are given in Supplemen-
tary Methods S1. 
2.2. Transfection of Mammary Cell Lines 
The S100P wild-type and mutated cDNAs in pET-15b were amplified by PCR using 
a pair of primers bearing (underlined) BamHI and HindIII restriction enzyme sites (for-
ward human S100P primer: 5’ CCGGATCC95ATGACGGAACTAGAGAC111 3’; reverse-
human S100P primer: 5’ GCAAAGCTT382TCATTTGAGTCCTGCC367 3’, numbering from 
GenBank Accession No NM_005980). The PCR products were cloned into pCDNA3.1(-) 
vector that had been doubly digested with BamHI and HindIII. Two to 3-μg recombinant 
construct were used to transfect the benign rat mammary tumour-derived cell line, Rama 
37 [26], using lipofectamine 2000 reagent (InVitrogen, Paisley, UK), and clones and pools 
of transfected cells were produced, as described previously [16,22], and maintained in 
medium containing 0.5 mg/mL Geneticin. 
2.3. Cell Migration Assays 
Cell migration assays, using 6.5-mm diameter Transwell permeable devices with 8.0-
μm pore size polycarbonate membranes, were carried out, as described previously, using 
a 1–5% (v/v) gradient of foetal calf serum and counting random fields [27] or using a 0.5–
10% (v/v) FCS gradient and counting 5 random fields [28]. Scratch migration assays were 
carried out using a Cell-IQ incubator, as described previously [29] and data analysed as 
indicated in the figure legends. In some migration experiments, a polyclonal goat S100P 
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antibody (Cat No. AF2957, R&D Systems, Abingdon, UK) was added to the culture me-
dium at the concentration indicated in the Figure legends. This antibody recognises wild 
type S100P, the K95A, and ΔK95 proteins. 
2.4. Metastasis Assays In Vivo 
Transfected cell clones and pools were subjected to assays for metastasis in rats, as 
described previously [3,21,23,25]. Transfected cultured Rama 37 cells (2 × 106 cells) synge-
neic to Furth Wistar rats (Olac, Banbury, UK) were injected subcutaneously without an-
aesthesia into the right inguinal mammary gland of 5- to 6-week old virgin females (80–
100g) during the morning in the University of Liverpool’s licensed (PCD 40/2408) Animal 
Facility, as described previously [23]. Rats were maintained 6 per cage at 19–21 °C, with a 
minimum 8h of light/day, bedded on straw, and fed Expanded Rat and Mouse Diet No 1 
(BP Ltd., Essex, UK) and tap water ad libitum. Tumours were monitored twice weekly 
and rats euthanised by CO2 overdose without anaesthetic after 2 months or earlier if show-
ing signs of stress. After autopsy, the primary and metastasis to the lungs were assessed, 
blinded and at random, as described previously [21,30]. Power calculations based on a 
reduction of 50% of metastasis in rats with 90% metastasis for p = 0.8, alpha = 0.05, yielded 
a minimum of 19 rats in each group. Lung tissue for detection of metastases was fixed in 
formalin, embedded in paraffin wax, sectioned, and stained with haematoxylin and eosin 
[26]. Lungs were scored positive for metastasis if lung nodules were present or negative 
if lung nodules were absent. 
2.5. Immunofluorescence Staining of Cultured Cells  
 Rama 37 cells (15,000 cells) expressing wild-type, K95A or ΔK95-mutant S100P, or 
cells transfected with empty vector were plated onto fibronectin-coated (2.5 μg/cm2) glass 
coverslips in 24-well plates, grown for 48 h, fixed, permeabilized, and blocked [28] (Sup-
plementary Methods S1), before being incubated with primary antibodies against 
NMMIIA (Covance, now Biolegend, Dedham, MA, USA), non-muscle myosin IIB 
(NMMIIB, Covance, now Biolegend, Dedham, MA, USA), S100P (BD, Oxford, UK or R&D 
systems Abingdon, UK), vinculin (Sigma, St Louis, MO, USA) paxillin (Invitrogen, Pais-
ley, UK), or eEF1A (clone CBP-KK1, mouse, Millipore, UK). Secondary antibodies were 
anti-rabbit or anti-mouse IgG conjugated with FITC (Dako, Ely, UK) or Cy-3 (Stratech Sci-
entific, Norfolk, UK). Quantitation of the immunofluorescence patterns of non-muscle 
myosin IIA and NMMIIB was carried out, as described previously [19]. For actin staining, 
0.6 μM rhodamine phalloidin (Invitrogen, Paisley, UK) was added with secondary anti-
bodies to the other IgGs. Numbers of focal adhesions were counted in randomly-selected 
cells from 3 independent experiments. For detection of cell surface S100P or eEF1A, the 
appropriate antibody was added to the culture medium for 1 h prior to fixation and block-
ing [16]. 
2.6. Isolation of Membrane Fractions  
 Cells were scraped into PBS and centrifuged at 300× g for 5 min. The pellet was re-
suspended in homogenisation buffer (250 mM sucrose, 50 mM Tris, 0.25 mM CaCl2 pH 
7.4), and centrifuged twice at 600× g for 5 min. The cell pellet was resuspended in homog-
enisation buffer, passed through a cell disruption bomb at 4 °C, 800–1000 PSI for 20 min, 
and the resulting suspension was centrifuged at 550× g for 10 min to remove remaining 
whole cells and nuclei. The supernatant was layered over 35% (w/w) sucrose/50 mM Tris, 
pH 7.4, centrifuged at 100,000× g for 1 h, the interface collected, diluted with 25mM su-
crose/50mM Tris pH 7.4, and centrifuged at 100,000× g for 30 min. The pellet containing 
plasma and other membranes was resuspended in 250 mM sucrose/50 mM Tris, pH 7.4. 
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2.7. Interaction between S100P and Recombinant NMMIIA 
Binding of recombinant (r)S100P variants to a recombinant protein consisting of the 
149 C-terminal amino acids of NMMIIA [31] was tested using a dual-Channel IAsys reso-
nant mirror biosensor (Neosensors, Sedgefield, UK), as described previously [22]. The re-
sulting association and dissociation curves fitted a single-site at least as well as a two-site 
binding model. 
2.8. Western Blotting  
Previously described methods of Western blotting of cell extracts from cloned and 
pooled transfected cells [21,22,32] and membrane fractions [28] were used.  
2.9. Statistical Analyses 
 Fisher’s exact test was used for statistical comparison of tumour incidence and me-
tastasis data in vivo and Mann–Whitney U-test for comparison of numbers of focal adhe-
sions, both using SPSS software. For multiple comparisons within the same data set, Bon-
ferroni or Dunnett multiple comparison with a control ANOVA post-hoc tests were used 
(Stats Direct Ltd., Cambridge, UK). 
3. Results 
3.1. The Effect of C-Terminal Mutants of S100P on Tumorigenesis and Metastasis  
The benign rat mammary tumour-derived cell line, Rama 37, has a long track record 
of testing for the metastatic potential of experimentally-expressed genes and proteins 
when injected into the mammary fat pads of immunocompetent syngeneic rats 
[3,23,25,33,34]. Genes and proteins, including S100P, which confer a metastatic phenotype 
upon the benign Rama 37 cells in this system, have subsequently been shown to be asso-
ciated also with reduced patient survival time when they are found in the cancer cells of 
human patients [3,35–37]. Transfected Rama 37 cell clones and pools expressing wild-type 
S100P, the K95A, or ΔK95 mutant S100P proteins exhibited similar incidences of mam-
mary tumour formation (Table 1). Thus, the C-terminal mutants did not affect the tumor-
igenicity of the cells. Cells expressing wild-type S100P exhibited high incidences of me-
tastasis, with 70% (cell clone) and 75% (cell pool) of tumour-bearing rats exhibiting lung 
metastases (Table 1), similar to those reported previously [3]. Examples of immunocyto-
chemical staining of the tumours and metastases arising from injection into the mammary 
fat pads of syngeneic rats of Rama 37 cells expressing wild-type S100P have been pub-
lished previously [3]. The cell clone and pool expressing K95A mutant S100P protein ex-
hibited incidences of metastasis of 33% and 47%, which were lower than those of the wild-
type clone and pool (Table 1). The transfected cell clones and pools expressing ΔK95 mu-
tant S100P protein exhibited incidences of metastasis (clone 16%, pool 11%), which were 
lower than wild-type S100P-expressing clone and pool (Table 1). Overall, mutation/re-
moval of the C-terminal amino acid of S100P significantly reduces its ability to cause me-
tastasis in a rodent model system in vivo. 
Table 1. Incidences of tumours and metastases. 
Transfected DNA (Designation 
of Cell Line)a 
Incidence of Mammary 
Tumours (%)b  p-Value
c 
Incidence of  
Metastasis (%)d p-Value
e  
None. Untransfectedf 18/20 (90)  0/18  
Rama 37 Vector onlyf     
Clone 19/20 (95)  0/19 (0)  
Pool 23/23 (100)  2/23 (9)  
S100P wild-type     
Clone 27/27 (100)  19/27 (70)  
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Pool 20/20 (100)  15/20 (75)  
K95A S100P     
Clone 21/21 (100) p > 0.9999 7/21 (33) p = 0.019 
Pool 19/19 (100) p > 0.9999 9/19 (47) p = 0.105 
ΔK95 S100P     
Clone 19/19 (100) p > 0.9999 3/19 (16) p = 0.0003 
Pool 19/21 (90) p > 0.9999 2/19 (11) p < 0.0001 
a Nomenclature—S100P wild type, cells expressing non-mutant S100P protein; K95A S100P, cells expressing S100P with 
C-terminal lysine changed to alanine; ΔK95 S100P, cells expressing S100P with C-terminal lysine deleted; clone, a cell line 
derived from a single colony of transfected cells; pool, an uncloned pool of transfected cells; experimental unit, clone or 
pool of transfected cells. b Number of tumours/number of animals inoculated. Animals were randomised before use to 
ensure individual observations were independent for statistical analysis, encrypted, and hence blinded to the recorder of 
macroscopic and histological results to avoid bias. No adverse effects reported. c p-values by standard 2-sided Fisher’s 
Exact test for tumour incidences in vivo of a clone or a pool of transfected cells expressing K95A or ΔK95 mutant S100P 
proteins compared with a clone or a pool of transfectant cells expressing wild-type S100P protein. d Numbers of animals 
(%) with lung metastases/numbers of animals with tumours. e p-values by standard 2-sided Fisher’s Exact test for inci-
dences of metastasis in vivo of a clone or a pool of transfected cells expressing K95A or ΔK95 mutant S100P proteins 
compared with a clone or a pool of transfectant cells expressing wild-type S100P protein. f For purpose of comparison 
only, the results for Rama 37 cells and vector are taken from Ismail, T. et al. [27], with permission of Oxford University 
Press. 
3.2. S100P Mutants and Altered Cytoskeletal Organisation  
Wild-type rS100P protein bound to rNMMIIA in vitro with a Kd of 370–470 nM (Sup-
plementary Table S1, Supplementary Figure S1), consistent with previously published 
values of 430–500 nM [19]. The K95A and ΔK95 mutant rS100P proteins exhibited 6 to 13-
fold reduced affinity for immobilised rNMMIIA (equilibrium Kd, 2.3 μM and 2.7 μM; ki-
netic Kd, 4.1 μM and 6 μM, respectively) than the wild-type protein, mainly due to an 8 
to 13-fold increased rate of dissociation (Supplementary Table S1). The observation that 
the association rate of S100P with NMMIIA in vitro was not affected by the C-terminal 
mutations but that the dissociation rate was suggests that the C-terminal lysine might be 
required not for initial binding but for structural stability of the complex. 
Immunofluorescence staining of fixed, control, S100P-negative Rama 37 cells re-
vealed cytoplasmic localisation of NMMIIA filamental structures along the edges of the 
cells (Figure 1a). In cells expressing wild-type S100P, there was a 20.5-fold reduction in 
the proportion of cells exhibiting this control cell distribution of NMMIIA (Supplementary 
Table S2; p < 0.0001). Whilst there was some background, possibly non-specific, staining 
for S100P in the S100P-negative cells (Figures 1b and 2b) that was not observed in Western 
blots (Figure 2a below and Supplementary Material S1 of Clarke et al. [16]), cells express-
ing wild-type S100P protein exhibited markedly stronger staining with intense foci of 
S100P in the cytoplasm and nuclear regions of the cells (Figure 1e). There were extensive 
clusters of NMMIIA foci, mainly at the cell periphery (Figure 1d), with only some colocal-
ising with S100P, predominantly in the perinuclear region of the cells (Figure 1f). The foci 
of S100P staining in the wild-type-S100P-expressing Rama 37 cells observed here is similar 
to that observed previously in MCF-7 cells [19] using a glass substratum; in contrast, in 
the present experiments, the cells were grown on a fibronectin substratum. Thus, the 
punctate staining pattern has been observed in two different cell systems, grown on two 
different substrata. However, the strong nuclear staining observed in the MCF-7 cells was 
not seen in the present experiments. The structural basis of the punctate staining of wild-
type S100P and how it might enhance cell migration in the MCF-7 cells [19] and in Rama 
37 cells in the present experiments is unknown. 
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Figure 1. Immunofluorescence localisation of NMMIIA and S100P in cloned transfected cells. Rama 
37 cells transfected with empty expression vector (Rama 37 + vector control; (a–c)) or Rama 37 cells 
overexpressing wild-type S100P (Rama 37 + S100P; (d–f)), K95A mutant S100P (Rama 37 + S100P 
K95A; (g–i)), or ΔK95 mutant S100P (Rama 37 + S100P ΔK95; (j–l)) were grown on fibronectin-coated 
coverslips for 48 h prior to fixation, permeabilisation, and staining using secondary antibody cou-
pled to fluorescein isothiocyanate for NMMIIA (a,d,g,j) or Cy-3 for S100P (b,e,h,k). Cells were then 
mounted and viewed using a Zeiss LSM510 confocal laser scanning microscope. Merged images 
(c,f,i,l) are shown with overlaps in yellow. Arrows in (a,c,g,j) show filamental structures along the 
edge of the cell. The arrow in (d) shows foci of NMMIIA staining near the leading edge of the cell, 
which did not co-localise with S100P (f). The arrows in (e,f) show a large focus of S100P co-staining 
with NMMIIA in the perinuclear region. Bars, 10 μm in all panels. 
Although cells expressing the S100P mutant proteins (Figure 1g–i,j–l) exhibited less 
intense fluorescence than the wild-type protein, they did not exhibit to the same extent 
the localised foci of S100P or NMMIIA found in cells expressing wild-type protein. In-
stead, clear filamental structures of NMMIIA were observed at the cell periphery (Figure 
1g,j) that resembled those observed in the control S100P-negative cells (Figure 1a). The 
proportion of K95A and ΔK95 mutant-S100P-protein-expressing cells that displayed a 
NMMIIA filamental structure resembling that of the S100P-negative control cells was not 
significantly different from the S100P-negative cells (K95A, p = 0.506; ΔK95, p = 0.818; Sup-
plementary Table S2). It has been reported that S100P does not bind to NMMIIB [19]. Thus, 
it might be expected that the presence of S100P would not be associated with altered cy-
toskeletal arrangement of NMMIIB. The percentage of S100P-negative and S100P-
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expressing cells that exhibited the NMMIIB filamental structure found predominantly in 
the S100P-negative control cells was determined. The results showed that for cells express-
ing wild-type S100P or the K95A or ΔK95 mutant proteins, the percentage of cells express-
ing the myosin distribution characteristic of the S100P-negative cells was not significantly 
different from the S100P-negative control cells (p = 0.973, 0.919, and >0.9999, respectively; 
Supplementary Table S3).  
In S100P-negative, non-metastatic control cells, vinculin and paxillin were com-
plexed into large foci at the ends of bundled actin filaments (Supplementary Figure S2). 
Cells expressing wild-type S100P exhibited a 4.3- or 3.5-fold reduction in the mean num-
ber of vinculin- or paxillin-positive focal adhesions per cell, respectively, compared to 
S100P-negative control cells (Table 2; both p < 0.0001). In contrast, cells expressing the 
K95A mutant S100P protein showed 2.1- and 1.8-fold higher numbers of vinculin and pax-
illin focal adhesions per cell, respectively, than wild-type S100P cells (vinculin and paxil-
lin, both p < 0.0001) but 48% and 53% of those in the S100P-negative, control cells (Table 
2; vinculin and paxillin, both p < 0.0001). ΔK95-mutant S100P protein exhibited mean num-
bers of vinculin and paxillin clusters per cell (Table 2) 5.1- and 4.5-fold higher, respec-
tively, than cells expressing wild-type protein (both p < 0.0001) but, surprisingly, also 1.2- 
and 1.3-fold higher than the control cells (vinculin, p 0.0017; paxillin, p < 0.0001). These 
results suggest that mutation/deletion of the C-terminal lysine reduces the ability of S100P 
to alter the cytoskeletal organisation, a possible consequence of the reduced interaction of 
S100P with NMMIIA.  
Table 2. Quantitation of focal adhesions in cell lines with and without metastatic potential. 
 Focal Vinculina Focal Paxillina 
Cell Clone 
No of Cells 
Counted 
Mean Focal  
Adhesions/ 
Cell ± SDb 
Mean Focal 
Adhesions 
as % of Vector 
Control 
No of Cells 
Counted 
Mean Focal  
Adhesions/ 
Cell ± SDb 
Mean Focal 
Adhesions 
as % of Vector 
Control 
Vector control 52 16.8 ± 4.0 100 54 15.2 ± 5.4 100 
Wild-type 
S100P 
51 3.9 ± 2* 23.2 53 4.4 ± 3.1** 28.9 
K95A-mutant 
S100P 52 8.1 ± 4.7
¶ 48.2 51 8.0 ± 4.2¶¶ 52.6 
ΔK95-mutant 
S100P 51 19.8 ± 6.2
§ 117.9 50 20.0 ± 5.2§§ 131.6 
a Cloned cell lines were stained for either vinculin or paxillin as described in Materials and Methods. Vinculin or Paxillin-
stained focal adhesions were counted in about 50 cells from three independent experiments and the mean and standard 
deviation (SD) of the number per cell were calculated. b Significance of difference between 2 variables identified was 
calculated using Mann–Whitney U-test. * Significantly fewer vinculin focal adhesions than S100P-negative vector clone 
control cells (p < 0.0001). ** Significantly fewer paxillin focal adhesions than S100P-negative vector clone control cells (p < 
0.0001). ¶ Significantly more vinculin focal adhesions than cell-clone-expressing wild-type S100P (p < 0.0001) but signifi-
cantly fewer than S100P-negative vector clone control cells (p < 0.0001) and cell-clone-expressing ΔK95 mutant S100P (p < 
0.0001). ¶¶ Significantly more paxillin focal adhesions than cell-clone-expressing wild-type S100P (p < 0.0001) but signifi-
cantly fewer than S100P-negative vector clone control cells (p < 0.0001) and cell-clone-expressing ΔK95 mutant S100P (p < 
0.0001). § Significantly more vinculin focal adhesions than cell-clone-expressing wild-type S100P (p < 0.0001) and signifi-
cantly more than S100P-negative vector clone control cells (p = 0.0017). §§ Significantly more paxillin focal adhesions than 
cell-clone-expressing wild-type S100P (p < 0.0001) and significantly more than S100P-negative vector clone control cells (p 
< 0.0001). 
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3.3. The Effect of S100P Mutants on Transwell and Scratch-Wound Cell Migration 
Given their reduction in metastatic potential and the key role of cell migration in 
metastasis [38], the effect of the C-terminal mutants on S100P-directed cellular migration 
was tested using two independent assays of cellular motility, Transwell migration [39], 
and scratch-wound closure [40,41] (Figure 3). In Figure 3, results of the Transwell migra-
tion assays are expressed as a percentage of the number of untreated, S100P-negative con-
trol cells passing through the membrane, whereas the results of the scratch migration as-
says are expressed as a percentage of the time-to-wound closure of untreated S100P-neg-
ative control cells (slower migration rate indicated by a longer time-to-wound-closure). 
Cells expressing wild-type S100P protein exhibited a 3-fold higher rate of Transwell mi-
gration than S100P-negative control cells transfected with empty vector (p < 0.0001, Figure 
3a). In contrast, cells expressing the K95A or ΔK95 mutant S100P proteins exhibited 
Transwell migration rates that were reduced to 35 and 38%, respectively, of that of cells 
expressing wild-type S100P protein (K95A and ΔK95 both p < 0.0001) and not significantly 
1.13- and 1.22-fold higher than S100P-negative, control cells (K95A, p = 0.695; ΔK95, p = 
0.147; Figure 3a and Supplementary Figure S3). 
Since migration rates in Transwell chambers are influenced by serum chemotaxis, 
directional cellular migration was tested using a scratch-wound assay. The wild-type 
S100P-expressing cells closed the scratch wound 1.7-fold faster than the S100P-negative 
control cells (p < 0.0001, Figure 3b and Supplementary Figure S4); however, cloned cells 
expressing the K95A or ΔK95 mutant S100P proteins closed the scratch wound 63% and 
62.5%, respectively, slower than cells expressing wild-type S100P (K95A and ΔK95, both 
p< 0.0001; Figure 3b and Supplementary Figure S4) and just 1.06- and 1.06-fold faster than 
S100P-negative, control cells (K95A, p = 0.172; ΔK95, p = 0.126; Figure 3b). These results 
show that the presence of the C-terminal lysine of S100P is associated with the S100P-
enhanced cell migration. 
3.4. Effect of 6-Aminocaproic Acid or S100P Antibody on the Migration of Rama 37 Cells 
Expressing Wild-Type or Mutant S100P Proteins  
S100P enhances plasminogen activation by tissue plasminogen activator in a C-ter-
minal lysine dependent manner and the activation is competed by the lysine analogue, 6-
aminocaproic acid (6-ACA) [16]. Thus, in order to examine how the C-terminal lysine of 
S100P affects cell migration, 6-ACA was added to the medium of the cloned cell lines ex-
pressing wild-type or mutant S100P proteins or control S100P-negative cells, and its effect 
on cell migration was tested using Transwell and scratch-wound assays (Figure 3). The 
results of the Transwell migration assays are expressed as a percentage of the number of 
untreated, S100P-negative control cells passing through the membrane, whereas the re-
sults of the scratch migration assays are expressed as a percentage of the time-to-wound-
closure of untreated S100P-negative control cells (slower migration rate indicated by a 
longer time-to-wound-closure). 
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Figure 2. Association of S100P with cell membranes. (A) Total cell extracts and membrane fractions prepared as described 
in Materials and Methods from Rama 37 cells expressing S100P proteins and were subjected to Western blotting to detect 
S100P protein, the cytoplasmic marker, tubulin, and the plasma membrane marker, caveolin 1. (B) Living cells not express-
ing S100P (Rama 37 + vector control; panels a,b,c) or expressing wild-type S100P (Rama 37 + S100P; panels d,e,f), K95A 
mutant S100P (Rama 37 + S100P K95A; panels g, h, i), or S100P protein with the C-terminal amino acid deleted (Rama 37 
+ S100P ΔK95; panels j,k,l) were incubated with S100P antibody in the culture medium, and bound antibodies were de-
tected with Cy-3-labelled secondary antibody, as described in Materials and Methods and observed with a Zeiss LSM510 
confocal laser scanning microscope. Three separate typical fields are shown for each cell line. (C) Antibodies directed at 
S100P (panels a,f) or cytoplasmic protein, eEF1A (panels c,h), were added to the culture medium of living S100P-negative 
Rama 37 cells (Rama 37 + vector control; panels a,c) or S100P-positive Rama 37 cells (Rama 37 + S100P; panels f,h). Parallel 
cultures of S100P-negative cells (Rama 37 + vector control; panels b,d,e) and S100P-positive cells (Rama 37 + S100P; panels 
g,i,j) were permeabilised before being treated with the antibodies directed at S100P (permeabilised; panels b,g) or eEF1A 
(permeabilised; panels d,e,i,j). Following fixation, bound antibodies were detected with fluorescein isothiocyanate-conju-
gated secondary antibodies (Materials and Methods) and observed with a Zeiss LSM510 confocal laser scanning micro-
scope. Panels (e,j) show the same fields as panels (d,i), but the intensity of the fluorescence signal has been reduced to 
show individual cells. Bars, (B,C) = 50 μm. 
The addition of 10 mM 6-ACA to the medium of S100P-negative control cells had no 
effect on their migration in either Transwell migration (Figure 3a and Supplementary Fig-
ure S3; p = 0.248) or scratch-wound assay (Figure 3b and Supplementary Figure S4; p = 
0.999). However, in cells expressing wild-type S100P, 6-ACA significantly reduced motil-
ity in the Transwell migration assays by about 30% (Figure 3a and Supplementary Figure 
S3; p < 0.0001) and increased scratch-wound closure time by 35.6% (Figure 3b and Supple-
mentary Figure S4; p < 0.0001), but, importantly, for the Transwell assay, the migration 
rate was still 2.2-fold higher (Figure 3a and Supplementary Figure S3; p < 0.0001), and for 
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the scratch assay, time-to-wound-closure was still 25.7% shorter (Figure 3b and Supple-
mentary Figure S4; p < 0.0001) than for S100P-negative control cells. Thus, the lysine ana-
logue, 6-ACA at concentrations that effectively compete lysine-dependent activities [42] 
abolishes only ~50% of the wild-type S100P-dependent increase in two separate assays of 
cell migration.  
6-ACA had no effect on Transwell migration of cells expressing either K95A or ΔK95 
C-terminal mutant proteins (Figure 3a and Supplementary Figure S3; K95A, p = 0.843; 
ΔK95, p = 0.72). In the scratch-wound assay, 6-ACA had no effect on cells expressing the 
K95A mutant protein (p = 0.207) and a small (10.5%) inhibitory effect (p = 0.013) on the 
migration of cells expressing the ΔK95 mutant protein (Figure 3b and Supplementary Fig-
ure S4). However, as with the Transwell assay, the resulting rates of wound closure with 
6-ACA were not different from the S100P-negative control cells (Figure 3b and Supple-
mentary Figure S4; K95A, p = 0.963; ΔK95, p = 0.9996). Thus, in both assays of migration, 
the absence of the C-terminal lysine reduces the effect of 6-ACA on cell migration. 
In addition to its lysine competitive activity, which might not be entirely specific for 
the C-terminal lysine, 6-ACA has been reported to be taken up into cells, at least in a clin-
ical situation [43,44], and to affect plasmin activity [45]. Thus, to rule out these possibilities 
and to establish the extracellular location of the inhibitory effect of 6-ACA and to investi-
gate the involvement of activated plasmin, more-specific inhibitors and their effects on 
cell migration were tested. 
When an S100P antibody was present at a concentration of 0.2 ng/μL in the medium 
during migration assays, the migration of S100P-negative cells was not affected in either 
the Transwell (Figure 3a and Supplementary Figure S3; p = 0.187) or scratch-wound assays 
(Figure 3b and Supplementary Figure S4; p = 0.983); however, the migration of wild-type 
S100P-expressing cells was reduced by ~30% in the Transwell assays (Figure 3a and Sup-
plementary Figure S3; p < 0.0001), and there was a 28% increase in time-to-wound-closure 
(Figure 3b and Supplementary Figure S4; p < 0.0001) compared to untreated S100P-ex-
pressing cells. As with 6-ACA, importantly, S100P-dependent migration was only ~50% 
reduced, with the antibody-treated cells still migrating 2-fold faster than control, S100P-
negative cells in the Transwell (Figure 3a and Supplementary Figure S3; p < 0.0001) and 
22% faster in the scratch-wound assays (Figure 3b and Supplementary Figure S4; p < 
0.0001). Furthermore, the reduction in migration with extracellular antibody was not dif-
ferent from that observed with 6-ACA in both the Transwell (Figure 3a and Supplemen-
tary Figure S3; p = 0.7) and scratch-wound assays (Figure 3b and Supplementary Figure 
S4; p = 0.299). The presence of S100P antibody in the medium did not change the migration 
of cells expressing the K95A or ΔK95 mutant proteins in the Transwell (Figure 3a and 
Supplementary Figure S3; K95A, p = 0.185; ΔK95, p = 0.537) or scratch-wound assays (Fig-
ure 3b and Supplementary Figure S4; K95A, p = 0.306; ΔK95, p = 0.586), even though the 
antibody detected both wild-type and mutant S100P proteins in Western blots (Figure 2a). 
These results suggest that S100P exposure from outside the cell contributes ~50% of the 
S100P-dependent increased migration in both Transwell and wound-closure assays but 
not when S100P lacks the C-terminal lysine residue. 
3.5. Effect of Plasmin Inhibitors on the Migration of Rama 37 Cells Expressing Wild-Type and 
Mutant S100P Proteins  
The effects on cell migration of two plasmin inhibitors, aprotinin and α-2-antiplas-
min, were examined. Fifty μg/mL aprotinin or 10 μg/mL α-2-antiplasmin reduced the mi-
gration rates of wild-type S100P-expressing cells in the Transwell assay by 40% and 41%, 
respectively, compared to untreated cells (Figure 3c and Supplementary Figure S3; apro-
tinin; α-2-antiplasmin, both p < 0.0001). In the scratch-wound assay, time-to-wound-clo-
sure increased 25.4% for 25 μg/mL aprotinin (p = 0.001), 43.5% for 50 μg/mL aprotinin (p 
< 0.0001), and 37.8% for 10 μg/mL α-2-antiplasmin (p < 0.0001) (Figure 3d,e and Supple-
mentary Figure S4). However, as with 6-ACA and S100P antibody, the cells treated with 
plasmin inhibitors still exhibited migration rates that were greater than S100P-negative 
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control cells in Transwell (Figure 3c and Supplementary Figure S3; 50 μg/mL aprotinin, 
1.9-fold greater; α-2-antiplasmin, 1.8-fold greater, both p < 0.0001) and scratch-wound as-
says (Figure 3d and Supplementary Figure S4; aprotinin, 25 μg/mL, 44% greater, 50 
μg/mL, 36% greater; Figure 3e and Supplementary Figure S4, α-2-antiplasmin, 37% 
greater, all p < 0.0001). Neither aprotinin nor α-2-antiplasmin had any effect on the migra-
tion of the S100P-negative, control cells in either assay (Transwell assay, Figure 3c and 
Supplementary Figure S3; 50 μg/mL aprotinin, p = 0.24; α-2-antiplasmin, p = 0.3; scratch-
wound assay, Figure 2d and Supplementary Figure S4; 25 μg/mL aprotinin, 50 μg/mL 
aprotinin and α-2-antiplasmin, all p > 0.9999) nor on cells expressing the mutant proteins 
in either assay (Transwell assay, Figure 3c and Supplementary Figure S3; K95A, 50 μg/mL 
aprotinin, p = 0.824; α-2-antiplasmin, p = 0.947; ΔK95, 50 μg/mL aprotinin, p = 0.848; α-2-
antiplasmin, p = 0.742; scratch-wound assay, Figure 3d and Supplementary Figure S4; 
K95A, 25 μg/mL or 50 μg/mL aprotinin, p = 0.31; ΔK95, 25 μg/mL or 50 μg/mL aprotinin, 
p = 0.237; α-2-antiplasmin, Figure 3e and Supplementary Figure S4; ΔK95, p = 0.072). How-
ever, α-2-antiplasmin inhibited cells expressing the K95A mutant protein by a small but 
significant 8.3% (Figure 3e and Supplementary Figure S4, p = 0.01). Since only plasmin is 
inhibited by both aprotinin [46] and α-2-antiplasmin [47], and since similar reductions in 
the migration rates of the wild-type S100P-expressing cells by these two inhibitors are 
observed in both the Transwell assays (Figure 3c and Supplementary Figure S3; 50 μg/mL 
aprotinin, 40%; α-2-antiplasmin, 41%) and scratch-wound assays (Figure 3d,e and Sup-
plementary Figure S4; 50 μg/mL aprotinin, 43.5%; α-2-antiplasmin, 37.8%), the results 
strongly suggest that plasmin activity contributes but only in part to the S100P-enhanced 
migration in the wild-type S100P-expressing Rama 37 cells.  
The number of focal adhesions in S100P-expressing cells was not increased by the 
addition of 6-aminocaproic acid (vinculin p = 0.614, paxillin p = 0.488), the S100P antibody 
(vinculin p = 0.269, paxillin p = 0.972), aprotinin (paxillin, p = 0.19), or α-2-antiplasmin 
(paxillin, p = 0.4) (Supplementary Tables S4 and S5), strongly suggesting that the 
S100P/plasmin pathway does not involve alteration in the numbers of focal adhesions per 
cell, clearly distinguishing this pathway from that initiated by binding of S100P to 
NMMIIA.  
3.6. Membrane-Associated S100P  
A membrane fraction containing the cell surface marker Caveolin 1 was isolated by 
sucrose density gradient centrifugation (Materials and Methods). This membrane fraction 
contained almost undetectable levels of the cytoplasmic marker, tubulin (Figure 2A) but 
clearly contained S100P in cells expressing wild-type, K95A, or ΔK95 mutant S100P pro-
teins. S100P was undetectable in S100P-negative, vector-transfected cells (Figure 2A). 
Quantitation of Western blots of caveolin-containing membrane preparations and total 
cell lysates from two independent experiments showed that for cells expressing wild-type 
S100P, K95A, and ΔK95 mutant S100P proteins, a mean of 2.2% ± SD 0.95%, 1.7% ± 0.94%, 
and 3.6% ± 1.0% of the total S100P in cell lysates, respectively, was detected in the mem-
brane fractions. The membrane levels of the K95A and ΔK95 mutant proteins were both 
71% of the membrane level of the wild-type S100P protein. Direct analysis of the presence 
of S100P at the external cell membrane was also assessed using immunofluorescence stain-
ing of unpermeabilised living cells by S100P antibody added to the culture medium. An 
S100P signal was observed on the surface of cells expressing wild-type S100P (Figure 
2B(d–f)), K95A (Figure 2B(g–i)), and ΔK95 (Figure 2B(j–l)) mutants but not on the S100P-
negative control cells (Figure 2B(a–c)). Staining with antibody to the intracellular protein, 
eEF1A was virtually absent in unpermeabilised living cells (Figure 2C(c,h)) in contrast to 
the strong staining observed with permeabilised cells (Figure 2C(d,e,i,j)), showing that the 
surface staining for S100P (Figure 2B(d-f) and Figure 2C(f)) was not due to cell lysis. These 
results suggest that a similar small proportion of the cellular wild-type or mutant S100P 
was isolated with the cells’ membranes and show that the failure of the mutant proteins 
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Figure 3. Effect of 6-aminocaproic acid, S100P antibody, aprotinin, or α-2-antiplasmin on migration 
of cells expressing wild-type and mutant S100P proteins. Transwell migration assays (a,c) or scratch 
migration assays in a Cell-IQ incubator (b,d,e) were carried out as described in Materials and Meth-
ods for cells expressing wild-type S100P (Rama 37 + S100P), K95A-mutant of S100P (Rama 37 + S100P 
K95A), ΔK95 mutant of S100P (Rama 37 + S100P ΔK95), or cells not expressing S100P (Rama 37 + 
vector control). In (a,c), the number of cells passing through to the underside of the membrane in 16 
h were counted and are plotted as percentages of the mean number of untreated Rama 37 + vector 
control cells passing through the membrane. In (b,d,e), the times to scratch-wound closure are ex-
pressed as a percentage of the mean value for untreated Rama 37 + vector control cells. The effect 
on migration of cells of addition to the extracellular medium (upper and lower chambers in the case 
of Transwell assays) of 10 mM 6-aminocaproic acid (ACA, panels a,b) or of an R&D Systems poly-
clonal goat S100P-specific antibody (Cat No. AF2957) at a concentration of 0.2 ng/μL in the medium 
(Antibody, panels a,b) are shown. Each box and whisker plot shows the dispersion of data from 14 
(a) or 11–12 (b) wells in two independent experiments carried out at different times. (c) Effect on 
Transwell migration of 50 μg/mL aprotinin (Aprotinin) or 10 μg/mL α-2-antiplasmin (Antiplasmin) 
in the extracellular medium. (d) Effect on scratch-wound migration of 25 μg/mL aprotinin (Apro-
tinin 25) or 50 μg/mL aprotinin (Aprotinin 50) in the extracellular medium. (e) Effect of 10 μg/mL 
α-2-antiplasmin (Antiplasmin) on scratch-wound migration. Each box and whisker plot shows the 
dispersion of data from 14 (c) or 14–25 wells (d,e) in two independent experiments carried out at 
different times. In all panels, p-values are indicated for comparison between the box and whisker 
plots beneath the ends of the horizontal lines as not significant (n.s., p > 0.05), or significant * (p 
between 0.001 and 0.05) or ** (p < 0.0001). For clarity, some p-value comparisons are shown without 
lines and in red colour, as follows: (a), n.s., Transwell assay Rama 37 + S100P K95A or Rama 37 
+ΔK95 in the presence of 6-aminocaproic acid not significantly different from vector control (Dun-
nett post-hoc multiple comparison with a control); ** Rama 37 +S100P antibody significantly faster 
than Rama 37 + vector control, p < 0.0001; (b), scratch-wound assay, n.s. Rama 37 + S100P K95A or 
Rama 37 + ΔK95 in the presence of 6-aminocaproic acid not significantly different from vector con-
trol; ** Rama 37 +S100P antibody significantly faster than Rama 37 + vector control (p < 0.0001). In 
all boxes, the black diamond and line show the median value; the cross shows the mean value. The 
white circles outside the whiskers denote outliers of >1.5 times the interquartile range. 
3.7. The Effect of Extracellularly Added S100P on the Migration of S100P-Negative Control 
Cells 
To confirm that S100P can alter cell migration from outside the cells, recombinant 
(r)S100P was added at 10 μg/mL to the medium of S100P-negative empty vector control 
cells during migration assays, a concentration that activates plasminogen activators in 
Biomolecules 2021, 11, 1471 15 of 22 
 
vitro [16]. Addition of rS100P to the medium resulted in a 2-fold increase in migration in 
the Transwell assay (Figure 4a; p < 0.0001), less than the ~3-fold increase resulting from 
endogenously expressed S100P protein and an 18.6% decrease in time-to-wound-closure 
(Figure 4b; p < 0.0001). In the scratch-wound assay, increasing the extracellular concentra-
tion of rS100P to 20 or 40 μg/mL did not reduce the time-to-wound-closure observed with 
10 μg/mL (p = 0.583 and 0.11, respectively, Figure 4b), strongly suggesting that increasing 
the concentration of rS100P any further does not increase cell migration. Amounts of 10 
mM 6-ACA, S100P antibody, 50 μg/mL aprotinin, or 20 μg/mL α-2-antiplasmin abolished 
the extracellular recombinantly-added, S100P-dependent increase in cell migration to a 
level not different from migration in the absence of added S100P (Figure 4a; 6-ACA, p = 
0.41; anti-S100P antibody, p = 0.098; aprotinin, p = 0.483; α-2-antiplasmin, p = 0.695). In 
contrast, in the absence of added rS100P, none of these inhibitors significantly reduced 
cell migration (Figure 4a; 6-ACA, p = 0.055; anti-S100P antibody, significant increase, p = 
0.0002; aprotinin, p = 0.946; α-2-antiplasmin, p = 0.932). The results show that 6-ACA, apro-
tinin, S100P antibody, and α-2-antiplasmin each abolished completely the cell migration 
resulting from S100P outside the cell, with no inhibitory effect on S100P-independent cell 
migration.  
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Figure 4. Effect of extracellular addition of S100P on migration of S100P non-expressing cells in 
Transwell and scratch-wound migration assays. (a) Transwell migration assays were carried out as 
described in Materials and Methods. The number of S100P-negative Rama 37 empty-vector-trans-
fected control cells passing through to the underside of the membrane in 16 h in the presence of 10 
mM 6-ACA (Rama 37 + vector + 10 mM 6-ACA), R&D Systems polyclonal goat S100P-specific anti-
body, Cat. No AF2957 at a concentration of 0.2 ng/μL in the medium (Rama 37 + vector + S100P 
antibody), 50 μg/mL aprotinin (Rama 37 + vector + 50 μg/mL aprotinin), or 20 μg/mL α-2-antiplas-
min (Rama 37 + vector + 20 μg/mL antiplasmin), either in the absence (No S100P) or in the presence 
(+ S100P) of 10 μg/mL recombinant S100P (rS100P) were counted and are plotted as a percentage of 
the mean of untreated Rama 37 + vector control cells (Rama 37 + vector control). Each box and 
whisker plot shows the dispersion of data from 60 separate data points from 4 independent experi-
ments (control, 6-ACA, S100P antibody) or 10 to 30 data points from 2 independent experiments 
(aprotinin and antiplasmin) carried out at different times. (b) Rama 37 cells transfected with empty 
expression vector were subjected to scratch-wound assays in the absence of or in the presence of 
various concentrations of rS100P added to the extracellular medium and the time-to-scratch-closure 
recorded for 9 separate wells in two independent experiments carried out at different times. For 
both (a) and (b), p-values are indicated for comparison between the box and whisker plots beneath 
the ends of the horizontal lines as n.s. not significant (p > 0.05) or significant ** (p < 0.0001). In (a), for 
clarity, some p-value comparisons are shown without lines and in red colour, as follows: n.s., no-
S100P controls for 10 mM 6-ACA, 50 μg/mL aprotinin, and 20 μg/mL α-2-antiplasmin are not sig-
nificantly different from the no-S100P, no-addition control (p = 0.055, 0.946, 0.932, respectively, Dun-
nett post-hoc test), or * no S100P for 0.2 ng/μL S100P antibody, significantly faster than the no-S100P, 
no-addition control (p = 0.0002). In all boxes for (a,b), the black diamond and line show the median 
value; the cross shows the mean value. The white circles outside the whiskers denote outliers of >1.5 
times the interquartile range. 
4. Discussion 
For the first time, it is shown here that removing or replacing the single C-terminal 
lysine residue of S100P protein with alanine significantly reduces its ability to promote 
metastasis in a well-established animal model [23]. In this animal model metastasis is pre-
dominantly to lungs and, over a longer time frame, to liver. The present experiments were 
terminated after 2 months, so liver metastases were not observed. Human breast cancer 
also metastasises eventually to the bony skeleton. Although most of the changes in the C-
terminal lysine showed a significant reduction in metastasis, the pool of K95A S100P 
transfectants did not, suggesting that more rats than the 19 used were needed to achieve 
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statistical significance. However, the decreases in metastasis were closely mimicked by 
decreases in Transwell/scratch-wound migration and increases in focal adhesions/cell, 
suggesting that these processes are all linked and that these in-vitro processes may be 
used to substitute for metastasis assays in vivo.  
The K95A and ΔK95 mutants of S100P have been shown previously to abolish S100P 
invasion through Matrigel in a Transwell invasion assay [16]. Thus, the novel finding is 
now made that cells expressing C-terminal mutant S100P proteins exhibit reduced cell 
migration, the major driver of metastasis in this system [38]; increased actin/myosin or-
ganisation; and increased numbers of vinculin/paxillin focal adhesions when compared 
to cells expressing wild-type S100P. It is possible that the changes in focal adhesion num-
bers represent changes in focal adhesion turn-over rate; however, separate experiments in 
which S100P-expressing cells were gently removed from the substratum using hydrostatic 
pressure without detergent showed approximately the same numbers of focal adhesions 
in S100P-positive and S100P-negative cells. When the residue on the substratum was sub-
sequently treated with non-ionic detergents, the loss in the S100P-positive cells was then 
observed [48]. This result suggests that it is the more stable, non-ionic-detergent-resistant 
focal adhesions that are lost in the presence of S100P.  
In other model systems, S100P has been reported to affect metastasis or processes 
associated with metastasis. In pancreatic cell lines, the S100-protein-binding drug, 
cromolyn, reduced the size of metastases derived from BxPC3, Mpanc 96, and Panc-1 cells 
injected into immunocompromised mice [49]. Similarly, it has been shown that receptor 
for advanced glycation end products (RAGE) antagonist peptide (RAP) inhibited interac-
tion of S100P with this extracellular receptor and reduced not only growth and migration 
but also reduced activation of NFκB. Furthermore, RAP reduced metastasis in vivo of 
pancreatic tumours in immunocompromised mice, suggesting a role for RAGE in S100P-
associated metastasis [50]. However, in these immunocompromised systems, S100P af-
fected cell/tumour growth in contrast to the syngeneic, immunocompetent, mammary 
system of the present experiments in which the S100P mutants did not affect tumour in-
cidence. In breast cancer cell lines, it has been reported that the long non-coding RNA, 
NORAD, sequesters S100P, and its reduction in breast cancer cells allows S100P to exert 
its prometastatic roles [51]. However, such an upstream activation process does not affect 
the results presented here on the downstream mechanisms of metastatic activity of S100P.  
S100 proteins act intracellularly by interacting with partner proteins [52]; however, 
the interaction of S100P with its major targets, ezrin [17] and IQGAP [18], are not affected 
by deletion of some of the C-terminal amino acid residues of S100P [18,20]. S100P binds 
to the RAGE receptor on the cell surface [15]. The hydrophobic binding patch on calcium-
bound S100P responsible for this interaction includes G93 in the potentially unstructured 
C-terminal region of human S100P [15]. S100P has been shown to co-localise with 
NMMIIA and to interact with the S100-binding region of NMMIIA in living cells using 
fluorescence lifetime imaging [19]. The failure of the C-terminal lysine mutants to enhance 
cell migration in the present experiments is likely to be associated with the observed 10-
fold reduction in interaction between S100P C-terminal mutant proteins and NMMIIA in 
vitro. Since S100P is phylogenetically closely related to S100B, it is also possible that the 
interaction of S100P with NMMIIA follows a two-step interaction model in which the C-
terminus strengthens the target interaction, as has been proposed for the interaction of 
S100B with its targets [53]. The precise involvement of the C-terminal lysine of S100P in 
its interaction with NMMIIA will only become evident on determination of the full, three-
dimensional structure of the complex of S100P with NMMIIA. However, the determina-
tion of the three-dimensional structure of S100A4 in its complex with a peptide consisting 
of the binding site of human NMMIIA did not identify a direct role for the two C-terminal 
lysines of S100A4 in its stable complex with the NMMIIA sequence [13]. Furthermore, for 
S100A4, it has been suggested separately that the charged C-terminal lysines prevent 
binding of its C-terminal region to the target-binding, hydrophobic regions exposed upon 
calcium activation within an S100A4 dimer [54]. For S100P, the ΔK95 mutant possesses a 
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C-terminal hydrophobic leucine residue and the replacement K95A mutant, an alanine 
residue with a smaller hydrophobic sidechain, in both cases these alterations may possibly 
lead to hydrophobic interaction between the modified C-terminus and the hydrophobic 
core in an S100P dimer in the calcium-activated state. Such intramolecular blocking of the 
myosin binding sites may account for the reduction in myosin binding, consequent 
changes in the numbers of focal adhesions, reduction in myosin-associated cell migration, 
and metastasis. The S100P ΔK95 mutant was more effective at reducing the metastatic 
potential of the cells (Table 1), at restoring an S100P-negative filamental pattern of 
NMMIIA (Supplementary Table S2), and at restoring the presence of focal adhesions than 
the K95A mutant protein (Table 2), observations which reinforce the link between cyto-
skeletal changes and metastatic potential in these cells. Thus, differences in the hydropho-
bicity of the C-terminal leucine of the ΔK95 mutant and alanine of the K95A mutant may 
account for the observed weaker binding to myosin, higher number of focal adhesions, 
and larger reduction in metastasis observed with the ΔK95 mutant than with the K95A 
mutant. This mechanism provides a possible explanation for the dramatic consequences 
of C-terminal deletion on S100P function, since structural studies have failed to show a 
direct mechanistic role for the flexible C-terminal region of S100P [11] or S100A4 [13,55]. 
However, it should be noted that the three-amino-acid residues of the C-terminal region 
beyond helix 4 in calcium-bound S100P is much shorter than the eight residues of S100A4 
[11], and thus, the C-terminal region of S100P may not behave in the same way as that of 
S100A4 upon C-terminal lysine removal. 
The signalling pathways by which NMMIIA-interacting S100 proteins, such as S100P 
[19] or S100A4 [13], alter the numbers of focal adhesions is not presently known. Nor is it 
known how the reduced binding to NMMIIA of S100P arising from the C-terminal mu-
tants (Supplementary Table S1 and Figure S1) might affect other actomyosin signalling 
pathways.  
A second novelty of the present findings is the identification, using inhibitors, of a 
second pathway by which S100P promotes cell migration in a cellular system of S100P-
driven metastasis. This second migration pathway is associated with plasmin protease 
activity and does not involve changes in the focal adhesion complexes of cells (Supple-
mentary Tables S4 and S5). The presence of this second, NMMIIA-independent pathway, 
is suggested by previous experiments in HeLa cells, showing that upon knockdown of 
NMMIIA with specific siRNAs, there was still residual stimulation of cell migration due 
to S100P (Figure 2A of [19]). How plasmin may induce cell migration associated with me-
tastasis remains to be determined. In keratinocytes, extracellular plasmin increases chem-
otaxic but not chemokinetic migration [56]; in human bronchial epithelial cells, plasmin 
activates MMP-9 to enhance wound closure [57], and in endothelial cells, plasmin binds 
to cell-surface integrin, αvβ3 [58], or to integrin α9β1 in CHO cells [59]. Plasmin can re-
lease specific molecules from the extracellular matrix, such as cysteine-rich 61 protein, 
which supports endothelial cell migration [60], or CCL21, which supports migration of 
dendritic and T cells of the immune system [61]. 
Since in the present experiments, the plasmin pathway can be inhibited by an S100P-
specific antibody added to the cellular medium and because antibodies do not cross cell 
membranes [62], this pathway is likely associated with S100P exposure to the extracellular 
medium, unlike the myosin pathway above, which is driven by intracellular S100P. It is 
well established that the C-terminal lysine of the related protein, S100A10, activates plas-
minogen activation processes by being displayed on the outside of the cell surface [63]. 
The dimeric S100A10 protein constitutes two subunits of the annexin A2 tetramer [63], 
which associates with the cell membrane and displays the C-terminal lysines of S100A10 
to the external milieu, where they activate tissue plasminogen activator to convert plas-
minogen to plasmin. A similar association between annexin A2 and S100A4 has also been 
proposed [64]. However, it has not been possible yet to demonstrate interaction between 
S100P and annexin A2 [16]. Alternatively, it has been reported that secreted S100P protein 
interacts with the RAGE receptor at the cell surface [15], where plasmin activation events 
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could take place. However, how S100P might leave the cell without the presence of a se-
cretory signal is not presently known. 
The completely novel finding in the present work is the demonstration, in a well-
established model system of metastasis [3,23–25], of two concurrent pathways that acti-
vate cell migration, a major driver in metastatic cells [38]. On the one hand, the presence 
of the C-terminal lysine maintains the ability of S100P to interact with and inhibit the pre-
dominant cell-migration-inhibitory activity of NMMIIA through an intracellular focal ad-
hesion pathway; this interaction then enhances cell migration [19]. On the other hand, the 
C-terminal lysine also enables extracellular activation of plasminogen activation pro-
cesses, which are now shown to contribute to cell migration through a focal-adhesion-
independent mechanism. However, the precise molecular intermediates that link plas-
minogen activation and cell migration in this system remain to be determined. While these 
results suggest two separate pathways, one associated with changes in the numbers of 
focal adhesions and one that is not, it is not possible to rule out overlap of the two path-
ways at the level of any intracellular signalling induced by the activation of plasminogen. 
The results here show how S100P can affect more than one pathway of migration in a 
previously well-characterised cell system of metastasis [3,23] and identifies the C-termi-
nus of S100P as a potential target for simultaneously inactivating such multiple pathways 
of S100P-driven metastasis. 
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